# US 12,766,259 B2 · Blood glucose control system and method > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,766,259 B2 - Document ID: US12766259B2 - Status: Granted - Kind: B2 - Application number: 18/027,640 - Filed: 2020-10-26 - Published: 2023-11-30 - Granted: 2026-10-20 - Earliest claimed: 2020-09-22 - Assignees: CureStream Co.,Ltd; Postech Research and Business Development Foundation - Applicants: Curestream Co., Ltd.; Postech Research and Business Development Foundation - Inventors: Sung Min Park; Gang Wook Kim - Web page: https://patentgrep.com/patent/US12766259B2 ## CPC - A61M 5/1723: {using feedback of body parameters, e.g. blood sugar or pressure} - A61M 5/14244: {adapted to be carried by the patient, e.g. portable on the body} - A61M 5/16877: {Passive flow controllers; Devices for setting a flow rate (clamp-type valves A61M39/28)} - G16H 10/60: for patient-specific data, e.g. for electronic patient records - G16H 20/17: delivered via infusion or injection - G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems - A61M 2230/08: Other bio-electrical signals - G16H 20/60: relating to nutrition control, e.g. diets - G16H 40/67: for remote operation - A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)} - G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA ## Abstract A blood glucose control system according to an embodiment of the present invention includes a continuous blood glucose meter configured to continuously measuring blood glucose of a patient, a bio-signal sensor configured to acquire a bio-signal of the patient, a lifelog data collector configured to collect lifelog data of the patient, an insulin injection controller configured to determine an insulin injection amount and an injection rate based on one or more of blood glucose measurement information and blood glucose metabolism characteristic information received from the continuous blood glucose meter, the bio-signal acquired by the bio-signal sensor or a stress level of the patient indexed by the bio-signal, and the lifelog data collected by the lifelog data collector, and an insulin pump configured to inject insulin into a body of the patient according to the insulin injection amount and the injection rate determined by the insulin injection controller. ## Claims ### Claim 1 A blood glucose control system comprising: a continuous blood glucose meter configured to continuously measure blood glucose of a patient; a bio-signal sensor configured to acquire a bio-signal of the patient; a lifelog data collector configured to collect lifelog data of the patient; an insulin injection controller configured to, obtain an insulin activation curve from insulin activation peak time information of the patient; obtain a time-based blood glucose change amount from blood glucose measurement information of the patient; calculate, based on the insulin activation curve and treatment history information of the patient, an amount of remaining insulin that is not activated in the patient's body; determine, based on the patient's treatment history information, a variability of an insulin injection amount; predict an amount of blood glucose consumption from the lifelog data of the patient by considering an amount of physical activation of the patient; predict an amount of change in blood glucose by considering one or more of an amount of food and an amount of sleep of the patient; learn information on the time-based blood glucose change amount, the amount of remaining insulin, and the variability of the insulin injection amount, based on the insulin activation curve; learn information on the predicted amount of blood glucose consumption and the predicted amount of change in blood glucose, based on the lifelog data; learn information on the bio-signal of the patient or a stress level of the patient indexed based on the bio-signal, and determine the insulin injection amount and an injection rate based on a learned model; and an insulin pump configured to inject insulin into a body of the patient according to the insulin injection amount and the injection rate determined by the insulin injection controller. ### Claim 2 (depends on 1) The blood glucose control system of claim 1, wherein the bio-signal sensor includes one of an electrocardiogram sensor and a heart rate sensor and monitors a state of a cardiovascular system of the patient. ### Claim 3 (depends on 2) The blood glucose control system of claim 2, wherein the bio-signal sensor includes a respiration sensor and monitors a state of a respiratory system of the patient. ### Claim 4 (depends on 3) The blood glucose control system of claim 3, wherein the bio-signal sensor includes a processor and analyzes the bio-signal of the patient by using the processor to index the stress level of the patient. ### Claim 5 (depends on 1) The blood glucose control system of claim 1, wherein the lifelog data collector collects physical activation information of the patient measured by an activation tracker in conjunction with the activation tracker worn by the patient. ### Claim 6 (depends on 1) The blood glucose control system of claim 1, wherein the lifelog data collector collects meal information input by the patient in conjunction with a meal management application installed on a portable terminal of the patient. ### Claim 7 (depends on 1) The blood glucose control system of claim 1, wherein the lifelog data collector collects sleep information of the patient measured and analyzed by a sleep sensor in conjunction with the sleep sensor worn by the patient or the sleep sensor arranged near a sleeping patient. ### Claim 8 A blood glucose control method comprising: a step of receiving insulin activation peak time information of a patient and obtaining an insulin activation curve from the insulin activation peak time information; a step of acquiring blood glucose measurement information of the patient and deriving a time-based blood glucose change amount from the blood glucose measurement information; a step of calculating, based on the insulin activation curve and treatment history information of the patient, an amount of remaining insulin that is not activated in the patient's body; a step of determining, based on the patient's treatment history information, a variability of an insulin injection amount; a step of predicting an amount of blood glucose consumption from lifelog data of the patient by considering an amount of physical activation of the patient; a step of predicting an amount of change in blood glucose by considering one or more of an amount of food and an amount of sleep of the patient; a step of learning information on the time-based blood glucose change amount, the amount of remaining insulin, and the variability of the insulin injection amount, based on the insulin activation curve, and information on the predicted amount of blood glucose consumption and the predicted amount of change in blood glucose, based on the lifelog data, and information on a bio-signal of the patient or a stress level of the patient indexed based on the bio-signal, to update a learned model; and a step of determining, by an insulin pump, the insulin injection amount and an injection rate based on the learned model. ### Claim 9 (depends on 8) The blood glucose control method of claim 8, further comprising: a step of evaluating appropriateness of insulin injection by the insulin pump.